Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

Trastuzumab Pamirtecan Hits Phase 3 PFS End Point in HER2+ Metastatic Breast Cancer

September 12th 2025

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC

September 12th 2025

Frontline amivantamab plus lazertinib generated an OS benefit vs osimertinib in patients with EGFR-mutated NSCLC in the Asia cohort of the MARIPOSA trial.

IMM2510 Induces Early Efficacy in Advanced, Immunotherapy-Exposed Squamous NSCLC

September 12th 2025

The PD-L1– and VEGF-directed bispecific antibody IMM2510 proved active in patients with squamous NSCLC after prior chemotherapy and immunotherapy.

EMA Validates Marketing Authorization Application for T-DXd in HER2+ Metastatic Solid Tumors

September 11th 2025

The marketing authorization application submitted to the EMA for T-DXd in HER2-positive unresectable or metastatic solid tumors has been validated.

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma

September 11th 2025

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

Navigating Novel IO Regimens and ADCs in Lung Cancer With Drs Rodriguez, Olazagasti, and Roy

September 10th 2025

Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Reviewing Key Data in Resectable and ROS1+ NSCLC With Drs Florez and Sabari

September 9th 2025

Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Exploring the Latest in EGFR-Mutant Lung Cancer With Drs Ramalingam and Raez

September 8th 2025

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Ventana Assay Earns CE IVDR Approval in EU as Companion Diagnostic in HER2-Expressing Breast and Biliary Tract Cancers

September 5th 2025

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Tisotumab Vedotin Approved in Hong Kong for Recurrent or Metastatic Cervical Cancer

September 3rd 2025

Tisotumab vedotin is cleared in Hong Kong for the treatment of select patients with cervical cancer.

EU Approves MMR IHC Panel pharmDx as a Companion Diagnostic for Nivolumab/Ipilimumab in MSI-H/dMMR CRC

September 3rd 2025

The MMR IHC Panel pharmDx was certified in the EU as a companion diagnostic to identify patients with colorectal cancer eligible for nivolumab/ipilimumab.

Health Canada Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Epithelial Ovarian Cancer

September 3rd 2025

Health Canada approved mirvetuximab soravtansine for folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer.

OncLive’s August EMA Regulatory Recap: Key EU Approvals in Oncology

September 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

Zongertinib Earns Chinese Approval for Unresectable, Locally Advanced, HER2-Mutant NSCLC

September 2nd 2025

China’s NMPA approved zongertinib tablets for unresectable, locally advanced or metastatic, previously treated NSCLC with HER2 mutations.

ADX-2191 Scores Orphan Designation in Europe for Primary LBCL of Immune-Privileged Sites

August 29th 2025

The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

First-Line Anlotinib Plus Chemo Approved in China for Advanced Soft Tissue Sarcoma

August 29th 2025

The combination of anlotinib plus chemotherapy has been approved in China for the treatment of patients with advanced soft tissue sarcoma.

FDA’s Push for Faster Drug Reviews Intersects With Policy Shifts on EU-Imposed Tariffs

August 29th 2025

As the FDA aims to reduce drug review times, the 15% tariff rate imposed on pharmaceuticals from Europe could affect drug access in the oncology space.

Perioperative Tislelizumab Wins EU Approval for Resectable NSCLC at High Risk of Recurrence

August 27th 2025

The European Commission approved neoadjuvant tislelizumab plus chemotherapy, followed by adjuvant tislelizumab, for resectable non–small cell lung cancer.

European Commission Greenlights UM171 Cell Therapy for Hematologic Malignancies

August 27th 2025

UM171 cell therapy has earned European Commission approval for the treatment of patients with hematologic malignancies requiring HSCT.

Ivonescimab Plus Chemo Boosts OS in Pretreated EGFR+ NSCLC

August 26th 2025

Ivonescimab plus chemotherapy improved overall survival in previously treated, advanced non–small cell lung cancer harboring EGFR mutations.